Scancell confirms healthy balance sheet as iSCIB1+ moves towards Phase III trial

Scancell reported a narrowed operating loss of £8.9m for the six months to 31 Oct 2025 and cash of £8.6m at period end, with a further £3m R&D tax credit received post-period and funding into H2 2026 while it pursues partnerships and financing. The company secured US regulatory clearance to launch a global Phase III trial of lead immunotherapy iSCIB1+ (primary endpoint PFS) after Phase II results showed 74% PFS at 16 months (+24 percentage points vs. standard of care); management targets potential read-out and commercialisation in 2029 and expects Phase II Modi-1 data in H1 2026, while advancing antibody programmes via GlyMab with partner Genmab.

Analysis

Market structure: Scancell’s Phase‑3 move (iSCIB1+) shifts value toward companies owning biomarker‑driven immunotherapy combos; oncology partners (large cap pharms) and antibody-platform players (e.g., Genmab) are clear beneficiaries while commodity biotech contract manufacturers could see higher demand. The 74% PFS at 16 months vs SOC +24pp implies meaningful pricing power if replicated, but commercialization is back‑loaded (readout 2029) so near‑term supply/demand is about trial enrollment and partner capacity, not drug sales.

Risk assessment: Key tail risks are a negative Phase‑3 readout (binary downside >50% in equity), failure to secure partner financing before H2 2026 (current runway ~£11.6m incl. R&D credit), or regulatory requirement to change endpoints—any of which could force a dilutive raise. Near term (days–months) focus is on financing and FDA interactions; medium term (6–12 months) on Phase‑3 initiation and Modi‑1 H1 2026 data; long term (2027–2029) on readout and commercialization outcomes.

Trade implications: Tactical direct play is a small, idiosyncratic long in SCLP/SCNLF (1–2% portfolio) ahead of Phase‑3 start and partnership announcements, hedged by shorting XBI or buying XBI put spreads to limit sector beta. If liquid, buy 18–30 month call spreads on SCLP/SCNLF (caps downside premium) or take exposure to Genmab (GMAB) as a lower‑volatility partner play; exit on partner deal, positive interim signals, or if cash falls below £5m.

Contrarian angles: Consensus may over‑value Phase‑2 PFS because small cohorts and selection bias with biomarker enrichment can overstate effect size; conversely, the market may under‑value the biomarker’s ability to de‑risk Phase‑3 and raise partner valuation multiples. Historical parallels (early immunotherapy positives that failed in large randomized trials) counsel position sizing discipline; unintended outcomes include a low‑value licensing deal that crystallizes modest near‑term upside but removes later M&A upside.

Key Decisions for Investors

• Establish a 1–2% portfolio long in Scancell (AIM:SCLP or OTC:SCNLF) now to capture Phase‑3 initiation and potential partner announcements; size conservatively due to binary risk and set a hard stop at 40% drawdown or if reported cash falls below £5m.
• Hedge sector exposure by shorting an equal‑notional position in XBI (SPDR S&P Biotech ETF) or buy a 6–12 month XBI 10–15% OTM put spread sized to offset 50–75% of SCLP beta during trial initiation.
• If liquid options exist, buy an 18–30 month SCLP/SCNLF call spread (e.g., 2x notional long Jan‑2028 25% OTM call / short Jan‑2028 75% OTM call) to limit premium and retain asymmetric upside to 2029 readout.
• Take a 0.5–1% long position in Genmab (GMAB) as a lower‑volatility paired play to benefit from GlyMab progress; trim on announcement of a licensing deal for SC134 or iSCIB1+ (target: +20–30% move).
• Do not increase exposure beyond these levels until: (a) partner financing confirmed or cash runway extended beyond H2 2027, or (b) positive interim Phase‑3 safety/efficacy signals; treat Modi‑1 H1 2026 data and any FDA briefing minutes in next 60 days as binary catalysts to re‑weight.